Sclerostin monoclonal antibodies on bone metabolism and fracture healing

Expert Opinion on Investigational Drugs

Volumn 21, Issue 10, 2012, Pages 1523-1534

  Gamie, Zakareya ^a   Korres, Nectarios ^b   Leonidou, Andreas ^b   Gray, Andrew C ^a   Tsiridis, Eleftherios ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Bone; Density; Fixation; Fracture; Healing; Implant; Sclerostin

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PARATHYROID HORMONE; RECOMBINANT ANTIBODY; RECOMBINANT HORMONE; RECOMBINANT PROTEIN; ROMOSOZUMAB; SCLEROSTIN;

BONE DENSITY; BONE METABOLISM; DATA ANALYSIS; DOSE RESPONSE; DRUG TOLERABILITY; FRACTURE HEALING; GENE DELETION; HUMAN; IN VIVO STUDY; INFORMATION RETRIEVAL; MEDICAL RECORD; METAPHYSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FRACTURE HEALING; GENETIC MARKERS; HUMANS;

EID: 84866558030     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.713936     Document Type: Review

References (70)

1. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267-76 (Pubitemid 37522584)
2. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009;24:1651-61
3. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-7 (Pubitemid 41379516)
4. Ott SM. Sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab 2005;90:6741-3 (Pubitemid 41759344)
5. Glass DA II, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64 (Pubitemid 40585297)
6. Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 2011;6:e25900
7. Wijenayaka A, Kogawa M, Findlay D, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. ASBMR Annual Meeting Abstracts; 2011
8. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-9 (Pubitemid 351768804)
9. Li C, Ominsky MS, Tan HL, et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone 2011;49:1178-85
10. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578-88
11. Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 2011;63:2385-95
12. Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009;24:1662-71
13. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25:948-59
14. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010;25:2647-56
15. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26
16. Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010;25:2412-18
17. Agholme F, Isaksson H, Li X, et al. Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop 2011;82:628-32
18. Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005;87:731-41 (Pubitemid 40489347)
19. Tsiridis E, Morgan EF, Bancroft JM, et al. Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 2007;25:1193-203 (Pubitemid 47365293)
20. Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 2010;81:234-6
21. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010;25:404-14
22. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011;26:1012-21
23. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-89 (Pubitemid 32202753)
24. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-19 (Pubitemid 34031693)
25. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet 2003;63:192-7 (Pubitemid 36949919)
26. Van Bezooijen RL, Ten Dijke P, Papapoulos SE, et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319-27 (Pubitemid 40910321)
27. Liu M, Kurimoto P, Niu Q-T, et al. Effect of estrogen deficiency in sclerostin knockout mice. ASBMR Annual Meeting Abstracts; 2011
28. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283:5866-75
29. Morse A, McDonald MM, Kramer I, et al. Bone volume is not altered with unloading in the homozygous sclerostin knockout mouse. ORS Annual Meeting; 2012
30. Sarahrudi K, Thomas A, Albrecht C, et al. Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res 2012. [Epub ahead of print]
31. Li X, Warmington S, Xia XC, et al. Sclerostin antibody prevents bone loss and increases bone formation in female rats with high turnover due to ovariectomy. ASBMR Annual Meeting Abstracts; 2011
32. Li X, Warmington KS, Niu Q-T, et al. Sclerostin Inhibition by Monoclonal Antibody Reversed Trabecular and Cortical Bone Loss in Orchiectomized Rats with Established Osteopenia. ASBMR Annual Meeting Abstracts; 2010
33. Stolina M, Dwyer D, Niu Q-T, et al. Treatment With a Sclerostin Antibody Increased Osteoblast-derived Markers of Bone Formation and Decreased Osteoclast-related Markers of Bone Resortion in Ovariectomised Rats. ASBMR Annual Meeting Abstracts; 2010
34. Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther 2011;11:117-27
35. Hirano T, Burr DB, Turner CH, et al. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45 (Pubitemid 29153386)
36. Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16:157-65 (Pubitemid 32046201)
37. Kirmani S, Amin S, McCready LK, et al. Sclerostin levels during growth in children. Osteoporos Int 2012;23:1123-30
38. Tian X, Jee WS, Li X, et al. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011;48:197-201
39. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 2011;152:3312-22
40. Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density. Available from: http://clinicaltrials.gov/ct2/show/NCT00896532
41. A Study to Evaluate the Effect of AMG 785 on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass. Available from: http:// clinicaltrials. gov/ct2/show/NCT00950950
42. Virdi A, Sena K, Liu M, et al. Enhanced Peri-Implant Bone Formation and Fixation by Sclerostin Antibody in a Rat Ovariectomy Model. ASBMR Annual Meeting Abstracts; 2011
43. Sena K, Liu M, Ke HZ, et al. Sclerostin Antibody Increases Peri-implant Bone Formation in Sham-ovariectomised and Ovariectomised Rats. ASBMR Annual Meeting Abstracts; 2011
44. Virdi A, Sena K, Maletich J, et al. Bone implant fixation augmentation with anti-sclerostin antibody treatment in rats. J Bone Miner Res 2009;24:S375
45. Irish JM, Virdi AS, Sena K, et al. Sclerostin Antibody Enhances Bone-Implant Contact by Increasing Bone Formation and Inhibiting Bone Resorption. ORS Annual Meeting; 2012
46. Spatz J, Ellman R, Cloutier AM, et al. Treatment with Sclerostin Antibody Increases Bone Mass and Strength During Hindlimb Unloading. ASBMR Annual Meeting abstracts; 2011
47. Ke HZ, Xiang JJ, Li X, et al. Inhibition of sclerostin by systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in mice and rats. Trans Orthop Res Soc 2009;34:221
48. He YX, Liu Z, Man CW, et al. Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing in rat Osteotomy Model. ORS Annual Meeting; 2012
49. Virk M, Saquib S, Farhang A, et al. Influence of sclerostin antibody on bone repair in a rat femoral defect model. Trans Orthop Res Soc 2009;34:607
50. Alaee F, Tang A, Ominsky M, et al. Sclerostin Antibody Enhances Bone Repair in a Rat Femoral Defect Model. ASBMR Annual Meeting Abstracts; 2011
51. He Y, Liu Z, Tang T, et al. Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing in a Rat Osteotomy Model. ASBMR Annual Meeting Abstracts; 2011. [Epub ahead of print]
52. McDonald MM, Morse A, Mikulec K, et al. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 2012
53. Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing. Available from: http://clinicaltrials.gov/ct2/show/ NCT00907296
54. Study To Assess Fracture Healing With Sclerostin Antibody. Available from: http://clinicaltrials.gov/ct2/show/NCT01081678
55. Tsiridis E, Gamie Z, Conaghan PG, et al. Biological options to enhance periprosthetic bone mass. Injury 2007;38:704-13 (Pubitemid 46726314)
56. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65 (Pubitemid 41138937)
57. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15 (Pubitemid 37152030)
58. Halleux C, Hu S, Prassler J, et al. Infrequent Co-treatment and Sequential Treatment of Anti-sclerostin Antibody with Zoledronic Acid Restores and Maintains Bone Mass in Murine Osteoporosis Models. Proceedings of the ASBMR Annual Meeting; 2009
59. Court-Brown CM, Aitken S, Hamilton TW, et al. Nonoperative fracture treatment in the modern era. J Trauma 2010;69:699-707
60. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-18 (Pubitemid 43867702)
61. Zuckerman JD. Hip fracture. N Engl J Med 1996;334:1519-25 (Pubitemid 26166896)
62. Tsialogiannis E, Polyzois I, Oak Tang Q, et al. Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opin Ther Targets 2009;13:123-37
63. Shaffer A, Shonuga OA, Hirsch B, et al. Sclerostin Antibody Enhances Spine Fusion in a Rat Posterolateral Transverse Process Fusion Model: Preliminary Results. ASBMR Annual Meeting Abstracts; 2011
64. Shaffer AD, Shonuga OA, Hirsch BP, et al. Anti-Sclerostin (Scl-Ab) Increases Bone Mass and Fusion Volume in a Rat Posterolateral Spinal Fusion Model. ORS Annual Meeting; 2012
65. Johansson HR, Skripitz R, Aspenberg P. Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone. J Bone Joint Surg Br 2008;90:400-4 (Pubitemid 351428963)
66. Skripitz R, Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br 2001;83:437-40 (Pubitemid 32390361)
67. Zati A, Sarti D, Malaguti MC, et al. Teriparatide in the treatment of a loose hip prosthesis. J Rheumatol 2011;38:778-80
68. Oteo-Alvaro A, Matas JA, Alonso-Farto JC. Teriparatide (rh [1-34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening. Orthopedics 2011;34:e574-7
69. Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009;119:837-51
70. Niu Q-T, Li X, Ke HZ. Increased Subchondral Bone Mass with No Histological Changes in Articular Cartilage in Sclerostin Knockout Mice and Rats Treated with Sclerostin Monoclonal Antibody. ORS Annual Meeting; 2012